This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
(MedPage Today) -- The FDA approved the Esprit BTK everolimus-eluting scaffold system for chronic limb-threatening ischemia (CLTI) below the knee, Abbott announced on Monday. This system represents the first drug-eluting resorbable scaffold with.
The Neuroguard Integrated Embolic Protection (IEP) system is an experimental treatment for carotid artery stenosis, also known as carotid arterydisease, a condition in which fatty-waxy deposits known as plaque builds up and blocks the normal flow of blood in the large arteries on either side of the neck.
The study, called IVUS-DCB, is the first randomized controlled trial to demonstrate the clinical benefits of using IVUS in angioplasty procedures for peripheralarterydisease (PAD), a condition in which plaque builds up in arteries in the legs. The study was funded by Medtronic, Inc. and Korea United Pharm.
Some of the late-breaking topics that will be covered include transcatheter aortic valve replacement (TAVR), peripheralarterydisease (PAD), and pulmonary embolism (PE): Impact of Age on Procedural Timing for Asymptomatic Severe Aortic Stenosis: Results from the Early TAVR Trial The PERFORMANCE II Trial: A Prospective Multicenter Single Arm Investigation (..)
The prospective, international, multicenter single-arm observational study evaluated the treatment of de novo, restenotic or occluded iliac lesions in 160 patients with Rutherford Class 2-6 peripheralarterydisease using the Dynetic-35 cobalt chromium balloon-expandable stent system. At baseline, 12.5% Brodmann M.
However, when these arteries become narrowed or blocked conditions like PeripheralArteryDisease (PAD) can emerge, posing a threat to our overall health. Understanding PeripheralArteryDiseasePeripheralarterydisease or PAD is a condition in which plaque builds up in the arteries that lead to the legs and feet.
In the DA+DCB arm, there was a trend toward higher stent-free patency through 12 months (79.1% versus 68.1%, · P=0.09) and a significantly lower provisional stenting rate (9.5% in 11 RCTs) were also similar or better than meta-analysis rates for balloon angioplasty or DCB, with variations based on study design and artery level.3-6
(MedPage Today) -- For patients with peripheralarterydisease (PAD) and chronic limb-threatening ischemia, drug-eluting stents and drug-coated balloons did not improve amputation-free survival compared with balloon angioplasty alone in the BASIL.
a Mountain View, CA-based developer of novel, best-in-class bioresorbable scaffolds for treating peripheralarterialdisease (PAD), has announced the appointment of Josh Smale as its Vice President of Global Clinical and Scientific Affairs. Medical device company R3 Vascular Inc., Image courtesy: R3 Vascular Inc.
Clinical success was defined as optimal stent expansion after final treatment with no in-hospital major adverse cardiovascular event (MACE). stent expansion at Maximum Calcium Site 96.7% stent expansion at Maximum Calcium Site 96.7% interventional cardiologist at ZNA Cardiovascular Center in Antwerp, Belgium. .
FDA Breakthrough Device Designation accelerates the review process for novel technologies that may provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions, such as CAD, which impacts 7.8% Stent Related Adverse Events greater than 1 Year After PCI. of the U.S. population.
Publication date: Available online 5 August 2024 Source: The American Journal of Cardiology Author(s): Sameh Sayfo, Zachary P. Rosol, David Fernandez Vazquez, Mufaddal Mamawala, Blake M. Bruneman, Sarah G. Weideman, Kennedy S. Adelman, Minseob Jeong, Bala Ramanan, Shirling Tsai, Nicolas W. Shammas, Peter P. Monteleone, Aravinda Nanjundappa, Hung B.
Encouraged by the early clinical results, Efemoral Medical is now developing an additional device for treating below-the-knee (infrapopliteal) arteries in patients with CLTI. Diseased human arteries are most simply, reliably, and successfully treated with drug-eluting, balloon-expandable stents," said Lewis B.
CLTI is the most severe form of peripheralarterialdisease (PAD), estimated to affect 11% of the 200 million people suffering from PAD globally. degradation of magnesium observed 12 months after implantation in coronary arteries.4 2,3 It has shown 99.6%
"The roundtable provided a unique opportunity to identify knowledge gaps and discuss how IVUS can enhance our understanding and treatment of peripheralarterial and deep venous pathology." They also emphasized the need for further research and evidence to support the integration of IVUS into routine clinical practice.
Most have gotten used to egregiously bad coverage of current events that fills the pages of today’s New York Times, but even by their now very low standards a recent telling of a story about peripheralarterydisease was very bad. Dr. Dormu also performed a mechanical atherectomy of all three tibial vessels. 4.1.2017.
With the addition of Shockwave, Johnson & Johnson will expand its MedTech cardiovascular portfolio into two of the highest-growth, innovation-oriented segments of cardiovascular intervention – coronary arterydisease (CAD) and peripheralarterydisease (PAD).
Background:Symptomatic peripheralarterydisease (PAD) is prevalent and targeted therapies include optimal medical care (OMC), supervised exercise therapy (SET) and revascularization (ST). Although most PAD trials focus on objective outcomes, improvement in quality of life is important to the patient.
Large-scale observational data have demonstrated a robust, independent association of elevated lipoprotein(a) (Lp[a]) levels with atherosclerotic cardiovascular disease (CVD), stroke, and peripheralarterydisease.
This unique case highlights the diagnostic and therapeutic challenges of a patient with multiple vascular risk factors who suffered from strokes secondary to BHS.MethodsA 79‐year‐old man with a past medical history of peripheralarterydisease, abdominal aortic aneurysm, myocardial infarction with drug eluding stents (on dual antiplatelet therapy (DAPT)), (..)
years of age, P <0.001), cerebral or peripheralarterydisease (6.2% Women also had more cardiovascular risk factors, including hypertension (66.6% versus 63.2%; P <0.001), hyperlipidemia (68.9% versus 66.3%; P =0.004), older age (62.4±7.9 years of age versus 59.0±8.4 versus 43.4%; P <0.001).
Common Vascular Conditions We Treat Some vascular diseases affect your arteries while others occur in your veins. Atherosclerosis & ArterialDiseasesPeripheralArteryDisease (PAD) : A blockage in your legs. Carotid ArteryDisease : A blockage or narrowing in the arteries supplying your brain.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content